High survival in a patient with advanced lung cancer treated with Vaxira®

Abstract

Introduction: lung cancer is considered the malignant tumor that produces the most deaths in the world over other cancers with higher incidence, such as colon or breast cancer, since its detection in early stages is difficult and in 90 % of cases it is diagnosed in advanced stages, when treatment is no longer as effective. In Cuba, cancer constitutes the second cause of death. Tracheal, bronchial, and lung tumors are the ones with the highest incidence.

Objective: to present the case of a patient with advanced lung cancer who had a higher survival than expected for this stage of the disease.

Case presentation: a 70-year-old female patient with a cytohistological diagnosis of non-small cell lung carcinoma, stage IV, who received first-line oncospecific treatment with chemotherapy and radiotherapy, was then included in the RANIDO Phase III Clinical Trial, in the racotumomab group; patient survival was 32 months at diagnosis and 25 months at inclusion in the clinical trial.

Conclusions: in the case of this patient with advanced stage non-small cell lung cancer, the administration of the racotumomab vaccine increased her survival, compared to that reported in the reviewed literature